Full-Time

Staff Regulatory Affairs Specialist

Posted on 11/1/2025

Becton Dickinson

Becton Dickinson

10,001+ employees

Global medical devices and diagnostics provider

Compensation Overview

$130.4k - $215.2k/yr

Midland Park, NJ, USA + 1 more

More locations: San Diego, CA, USA

In Person

On-site requirement: at least 4 days per week.

Category
Legal & Compliance (2)
,
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Bachelor's degree, preferably in a life sciences field. Advanced degree preferred.
  • Minimum of 5 years Regulatory Affairs experience in medical devices, preferably sterile single-use disposable products.
  • Proven ability to resolve problems and make appropriate regulatory decisions.
  • Demonstrated success in the preparation and completion of 510(k) submissions.
  • Experience interfacing with FDA personnel during 510(k) review and meetings with the Agency.
  • Comprehensive knowledge of US medical device regulations including 21 CFR 820 - Quality System Regulation / design controls, consensus standards, and FDA guidance documents.
  • Strong critical thinking, communication, and project management skills.
  • Demonstrated global perspective, customer focus, cross-functional collaboration, and teamwork skills.
  • Current knowledge of European quality system standards and requirements under Medical Device Directive and Medical Device Regulation.
  • Ability to function in a matrix organization.
  • Proficient in using Microsoft Outlook, Word, Excel, PowerPoint, and Adobe.
Responsibilities
  • Coordinate, prepare, and complete premarket applications to the US FDA including Premarket Notification 510(k) and Pre/Q-Sub submissions in a timely manner. Act as liaison with FDA regarding product submissions.
  • Assess US regulatory requirements for proposed device modifications. Prepare robust non-filing justifications for changes that do not require a 510(k) submission.
  • Support technical files for submission to European Notified Bodies for timely CE marking of new and modified products, with appropriate input from supporting functions (R&D, Quality, Manufacturing, etc.).
  • Represent Regulatory Affairs and demonstrate leadership in complex product development teams by identifying and interpreting relevant regulatory requirements and providing useful regulatory guidance throughout the product development cycle prior to regulatory submission.
  • Identify and communicate appropriately quantified risks and mitigation strategies associated with regulatory strategies to collaborators.
  • Support development and execution of global regulatory strategies by collaborating closely with international regulatory associates to register our devices worldwide.
  • Lead regulatory efforts required to align with new regulations and requirements.
  • Review and approve product labeling, promotional, and advertising materials to ensure regulatory compliance.
  • Prepare, submit, and maintain global regulatory submissions and registrations.
  • Write and update standard operating procedures, work instructions, and policies to maintain compliance with applicable regulations and standards.
  • Coordinate and respond to customer requests for product information.
  • May represent BD in relevant external trade organizations and regulatory standards development to support BD’s continuous product development and compliance efforts.
  • Working knowledge of regulations for sterile class II devices, preferably related to IV infusion disposables.
  • Identify current work process inefficiencies and implement improvements.
  • Execute the above tasks with limited supervision.

BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Franklin Lakes, New Jersey

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Drug-delivery devices drive 4.7% medical essentials revenue growth in Q2 2026.
  • Interventional segment surges 7.3% from Urology, Peripheral Intervention demand.
  • AI Pyxis Pro partnership with Wellstar enhances connected care across Georgia hospitals.

What critics are saying

  • Waters erodes BD diagnostics share with BACTEC FXI detecting infections 3 hours faster.
  • Quvara poaches BD contracts using Swindon plant and 300 transferred employees.
  • Post-$17.5B Biosciences divestiture projects 1.8% annual revenue decline to 2029.

What makes Becton Dickinson unique

  • BD leads in three segments: Medical, Life Sciences, and Interventional since 1897.
  • BD Excellence initiative expands gross margins to 54.9% in Q2 FY2025.
  • CentroVena One launches as first all-in-one US central venous catheter system.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Tuition Reimbursement

Company News

Yahoo Finance
Apr 14th, 2026
BD reports Q2 earnings with 6% revenue growth but organic sales miss expectations at 0.9%

Becton Dickinson reported second-quarter fiscal 2025 results with revenue growing 6%, or 0.9% organically, falling below expectations. The medical device company cited market challenges in its Life Sciences segment, including changes in research funding policy and slower-than-expected recovery in blood culture testing within Diagnostics. Chairman and CEO Tom Polen acknowledged dissatisfaction with the top-line performance, noting it doesn't reflect the mid-single-digit growth BD has consistently delivered in recent years. The company is implementing strategic actions and investments to reaccelerate organic sales growth. Despite revenue challenges, BD exceeded adjusted earnings per share expectations, delivering adjusted gross margins of 54.9%, up 190 basis points year-over-year. This marks the fourth consecutive quarter of strong gross margin expansion driven by the company's BD Excellence initiative.

PR Newswire
Apr 9th, 2026
Rick Byrd to retire from BD.

Rick Byrd to retire from BD. Apr 09, 2026, 16:05 ET FRANKLIN LAKES, N.J., April 9, 2026 /PRNewswire/ - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Richard (Rick) Byrd has informed the company of his intent to retire after nearly 25 years with BD. Byrd is currently executive vice president and president of the Interventional Segment at BD, a position he has held since September 2022. During his tenure, Byrd held several leadership roles including worldwide president of Medication Delivery Solutions and worldwide president of Preanalytical Systems. Prior to joining BD in 2004, Byrd held various leadership and engineering positions across the medical device and advanced technology sectors. "Over his long career, Rick has led his teams to deliver meaningful results for BD - strengthening our portfolio, elevating our operational rigor and advancing BD's role as a global healthcare leader," said Tom Polen, chairman, CEO and president of BD. "Rick has driven impact across multiple segments, including expanding BD's leadership in Vascular Access Management, advancing our 'One-Stick Hospital Stay' vision and leading critical manufacturing scale-up efforts during the COVID-19 pandemic. We thank Rick for his many contributions to BD and wish him all the best in his retirement." Byrd will remain in his role through June. BD intends to name a successor prior to Byrd's retirement date. "What has inspired me most throughout my time at BD is the people - the teams who show up every day committed to driving the future of care and improving outcomes for patients everywhere," Byrd said. "I'm incredibly proud of the meaningful work we've accomplished together and am confident that BD will continue to deliver on its purpose of advancing the world of health." About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson. | Contacts: | / | | Media | Investors | | Megan Dubrowski Senior Director, Executive Communications [email protected] | Shawn Bevec SVP, Investor Relations [email protected] | SOURCE BD (Becton, Dickinson and Company)

PR Newswire
Apr 8th, 2026
BD gains CE Mark for adjustable Liverty TIPS Stent Graft in EU portal hypertension care

BD has received CE Mark approval for its Liverty TIPS Stent Graft, bringing next-generation portal hypertension treatment to the European Union. The device features an adjustable 6–10mm inner diameter and offers the broadest range of covered stent lengths currently available for transjugular intrahepatic portosystemic shunt procedures. Designed for patients with cirrhosis complications, the device uses a flexible nitinol frame and dual-layer ePTFE encapsulation delivered via a triaxial system. An estimated 58 million people worldwide live with cirrhosis, which can lead to life-threatening portal hypertension complications. Safety and effectiveness data from the pivotal ARCH clinical trial will be presented at the Society of Interventional Radiology Annual Scientific Meeting on 12 April 2026. The device remains investigational in the United States.

BD
Apr 8th, 2026
BD delivers next-generation TIPS innovation to advance portal hypertension care across the European Union.

BD delivers next-generation TIPS innovation to advance portal hypertension care across the European Union. CE Marking and ARCH clinical trial data position the Liverty(TM) TIPS Stent Graft to expand treatment options for patients with advanced liver disease FRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced application of CE Mark for the Liverty(TM) TIPS Stent Graft, delivering innovation to portal hypertension care across the European Union. Designed to expand treatment options for patients with cirrhosis and complications of portal hypertension, our next-generation, adjustable-diameter device represents the latest advancement by BD in interventional therapies addressing complex liver disease. Safety and effectiveness data from the pivotal ARCH clinical trial evaluating the Liverty(TM) TIPS Stent Graft will be presented for the first time at the Society of Interventional Radiology (SIR) Annual Scientific Meeting on April 12, 2026. Cirrhosis remains a significant global health challenge, with an estimated 58 million people worldwide living with the disease, according to the latest findings from the Global Burden of Disease study.[1] Cirrhosis can lead to portal hypertension, a serious condition that can result in life-threatening complications such as variceal bleeding and fluid build-up in the abdomen or chest. [2] Transjugular intrahepatic portosystemic shunt (TIPS) procedures help reduce symptoms caused by elevated portal pressure by lowering that pressure and improving blood flow. The Liverty(TM) TIPS Stent Graft is engineered to support individualized patient management, offering a 6-10 mm adjustable inner diameter and the broadest range of covered TIPS stent lengths currently available. Key features include a flexible, self-expanding nitinol frame and dual-layer ePTFE encapsulation with carbon impregnation on the inner surface, delivered fully constrained on a triaxial delivery system designed for placement accuracy, control and ease of use. "For patients living with complications of portal hypertension, access to safe, effective and adaptable treatment options is critical," said Rima Alameddine, worldwide president of Peripheral Intervention at BD. "With CE Marking of the Liverty(TM) TIPS Stent Graft, we're introducing an innovative, adjustable solution that helps physicians personalize therapy and improve the potential for long-term outcomes." BD also announced that data from the ARCH clinical study, a global, prospective, multi-center, single-arm clinical study assessing the safety and effectiveness of the Liverty(TM) TIPS Stent Graft for the treatment of complications from portal hypertension, will be presented for the first time on podium by Global Principal Investigator Prof. Ziv Haskal, MD, at SIR in April. "The Liverty(TM) TIPS Stent Graft represents an important advancement in how we care for patients with the serious complications of portal hypertension," said Dr. Haskal. "Its adjustable diameter and delivery design allow physicians to better match the shunt to a patient's unique physiology, a key consideration in safe and effective TIPS creation. The trial provides the first and only prospective data describing the results of small diameter calibrated TIPS for treating all the major complications of portal hypertension. I look forward to presenting the ARCH study results at SIR." In the United States, the Liverty(TM) TIPS Stent Graft it is an investigational device limited by U.S. law to investigational use only. About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson. ________________________________ [1] Duo H, You J, Du S, Yu M, Wu S, Yue P, et al. Liver cirrhosis in 2021: Global Burden of Disease study. PLOS One. 2025;20(7):e0328493. doi: 10.1371/journal.pone.032849 [2] Carroll A, Boike JR. Tips for TIPS recipients: A patient-focused guidance on TIPS. Clin Liver Dis (Hoboken). 2024;23(1):e0091. doi:10.1097/CLD.0000000000000091 SOURCE BD (Becton, Dickinson and Company) Released April 8, 2026

The News Courier
Apr 7th, 2026
When every beat matters, BD helps clinicians eliminate blind spots with continuous, noninvasive blood pressure insight.

When every beat matters, BD helps clinicians eliminate blind spots with continuous, noninvasive blood pressure insight. PR Newswire Today at 3:50am PDT New HemoSphere Stream(TM) Module expands access to continuous, noninvasive arterial waveform data across compatible bedside monitors and broader care settings, giving more clinicians real-time insight into more patients. FRANKLIN LAKES, N.J., April 7, 2026 /PRNewswire/ - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the HemoSphere Stream(TM) Module, a new innovation which gives clinicians continuous, noninvasive visibility into patients' blood pressure. The module delivers real-time, beat-to-beat arterial waveform data from a noninvasive finger cuff directly to compatible multiparameter patient monitors, helping clinicians close gaps between intermittent readings. "We're delivering real-time visibility of hemodynamic changes to more patients and care settings by making continuous, noninvasive monitoring available on compatible multiparameter monitors." said Tim Patz, worldwide president of Advanced Patient Monitoring at BD. "Patients who may not require an invasive arterial line can now benefit from continuous blood pressure monitoring, rather than intermittent checks." The compact HemoSphere Stream(TM) Module mounts easily to an IV pole, taking no additional footprint in clinical environments. When used with the VitaWave(TM) Plus Finger Cuff, the HemoSphere Stream(TM) Module serves as the interface that delivers continuous, noninvasive arterial blood pressure waveform data to compatible multiparameter monitors. Together with the finger cuff and supporting accessories, it comprises the VitaWave(TM) Plus System, which is designed for accuracy using technology validated against arterial line measurements. "Monitoring blood pressure and perfusion during and after surgery is key to reducing major complications after surgery. Anesthesia providers have been waiting for the availability of a simple way to measure continuous blood pressure noninvasively. This is a landmark technology to improve global patient safety," said Michael Scott, MD, Chair APSF Clinical Deterioration Committee. Continuous blood pressure helps reveal hemodynamic changes that may occur between intermittent blood pressure checks, which are typically taken every 3-5 minutes in the operating room. By providing a real-time view into blood pressure trends on any compatible patient monitor, the VitaWave(TM) Plus System supports the Anesthesia Patient Safety Foundation's (APSF) recommendations for continuous noninvasive hemodynamic monitoring to detect and treat intraoperative hypotension sooner. Visit www.bd.com/HemoSphereStream for more information about BD's Advanced Patient Monitoring solutions including HemoSphere Stream(TM) Module and VitaWave(TM) Plus System. About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson. | Contacts: | / | | Media | Investors | | Matt Marcus VP, Public Relations [email protected] | Shawn Bevec SVP, Investor Relations [email protected] | CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events. SOURCE BD (Becton, Dickinson and Company) This is a paid placement. For further inquiries, please contact PR Newswire directly.

INACTIVE